These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 26862736)
21. ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC). Witta SE; Dziadziuszko R; Yoshida K; Hedman K; Varella-Garcia M; Bunn PA; Hirsch FR Ann Oncol; 2009 Apr; 20(4):689-95. PubMed ID: 19150934 [TBL] [Abstract][Full Text] [Related]
23. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents. Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218 [TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells. Belleudi F; Marra E; Mazzetta F; Fattore L; Giovagnoli MR; Mancini R; Aurisicchio L; Torrisi MR; Ciliberto G Cell Cycle; 2012 Apr; 11(7):1455-67. PubMed ID: 22421160 [TBL] [Abstract][Full Text] [Related]
25. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers. Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253 [TBL] [Abstract][Full Text] [Related]
26. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells. Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492 [TBL] [Abstract][Full Text] [Related]
27. Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines. Hanke NT; Garland LL; Baker AF J Cancer Res Clin Oncol; 2016 Mar; 142(3):549-60. PubMed ID: 26385374 [TBL] [Abstract][Full Text] [Related]
28. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692 [TBL] [Abstract][Full Text] [Related]
29. Valproic acid (VPA) enhances cisplatin sensitivity of non-small cell lung cancer cells via HDAC2 mediated down regulation of ABCA1. Chen JH; Zheng YL; Xu CQ; Gu LZ; Ding ZL; Qin L; Wang Y; Fu R; Wan YF; Hu CP Biol Chem; 2017 Jun; 398(7):785-792. PubMed ID: 28002023 [TBL] [Abstract][Full Text] [Related]
30. ErbB3 mRNA expression correlated with specific clinicopathologic features of Japanese lung cancers. Kawano O; Sasaki H; Endo K; Suzuki E; Haneda H; Yukiue H; Kobayashi Y; Yano M; Fujii Y J Surg Res; 2008 May; 146(1):43-8. PubMed ID: 17631905 [TBL] [Abstract][Full Text] [Related]
32. Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in non-small cell lung cancer cells. Gavrilov V; Lavrenkov K; Ariad S; Shany S Anticancer Res; 2014 Nov; 34(11):6565-72. PubMed ID: 25368259 [TBL] [Abstract][Full Text] [Related]
33. Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors. Aurisicchio L; Marra E; Luberto L; Carlomosti F; De Vitis C; Noto A; Gunes Z; Roscilli G; Mesiti G; Mancini R; Alimandi M; Ciliberto G J Cell Physiol; 2012 Oct; 227(10):3381-8. PubMed ID: 22213458 [TBL] [Abstract][Full Text] [Related]
34. Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression. Terranova-Barberio M; Roca MS; Zotti AI; Leone A; Bruzzese F; Vitagliano C; Scogliamiglio G; Russo D; D'Angelo G; Franco R; Budillon A; Di Gennaro E Oncotarget; 2016 Feb; 7(7):7715-31. PubMed ID: 26735339 [TBL] [Abstract][Full Text] [Related]
35. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. Booth L; Roberts JL; Tavallai M; Webb T; Leon D; Chen J; McGuire WP; Poklepovic A; Dent P Oncotarget; 2016 Apr; 7(15):19620-30. PubMed ID: 26934000 [TBL] [Abstract][Full Text] [Related]
36. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells. Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604 [TBL] [Abstract][Full Text] [Related]
37. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. Nakagawa T; Takeuchi S; Yamada T; Ebi H; Sano T; Nanjo S; Ishikawa D; Sato M; Hasegawa Y; Sekido Y; Yano S Cancer Res; 2013 Apr; 73(8):2428-34. PubMed ID: 23382048 [TBL] [Abstract][Full Text] [Related]
38. Paeoniflorin Potentiates the Inhibitory Effects of Erlotinib in Pancreatic Cancer Cell Lines by Reducing ErbB3 Phosphorylation. Hao J; Yang X; Ding XL; Guo LM; Zhu CH; Ji W; Zhou T; Wu XZ Sci Rep; 2016 Sep; 6():32809. PubMed ID: 27609096 [TBL] [Abstract][Full Text] [Related]
39. Histone deacetylase inhibitors induced differentiation and accelerated mineralization of pulp-derived cells. Duncan HF; Smith AJ; Fleming GJ; Cooper PR J Endod; 2012 Mar; 38(3):339-45. PubMed ID: 22341071 [TBL] [Abstract][Full Text] [Related]
40. Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications. Gray SG; Al-Sarraf N; Baird AM; Cathcart MC; McGovern E; O'Byrne KJ Eur J Cancer; 2009 Nov; 45(17):3087-97. PubMed ID: 19818596 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]